TORONTO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- a health-tech company that leverages advancements in science and technology to build breakthrough ventures that transform human wellness, is pleased to announce that its U.S.
biosciences subsidiary Mikra Cellular Sciences Inc. ("Mikra") has begun shipping initial preorders of its new product, Developed in close collaboration with six-time MLB All-Star, three-time Silver Slugger and Olympic medal winner José Bautista, combines a precision blend of citicoline, tyrosine and pure lion's mane mushroom to deliver improved memory, total concentration and faster cognition without any caffeine or stimulants. “We are delighted to report that we have started shipping preorders of ahead of schedule,” said Andrea Judge, CEO of Mikra.
“Though it was originally announced that would ship in the 4 quarter of this year, Team Mikra has consistently beaten its own internal projections and advanced the shipment and launch dates at every key milestone. We are determined to deliver a compelling marketing push for the formal launch next month in close partnership with José and give our customers a product experience that surpasses their high expectations.” combines the clinically studied neuroprotective and cognition-enhancing effects of pure citicoline with the performance-preserving and enhancing effects of tyrosine and pure lion’s mane mushroom.
A systematic review of the medical use of citicoline published in the Swiss journal found: A Mt. Sinai Hospital clinical abstract on the medical use of tyrosine reported: Finally, a landmark Japanese randomized control trial of lion’s mane mushroom demonstrated: features a proprietary precisely dosed blend of citicoline, tyrosine and pure lion's mane mushroom as its primary active ingredients. All three have been extensively studied and convincingly found to support enhanced focus, improved memory and clearer cognition in published, peer-reviewed clinical research.
Mikra is pushing biosciences beyond the expected with the belief that it is possible to add more active, vigorous, enjoyable, and valuable years to your life through protecting and maintaining your cellular health. Lifeist is committed to bringing natural products backed by real science to market and looks forward to reaching many more customers in 2024 and beyond. Sitting at the forefront of the post-pandemic wellness revolution, Lifeist leverages advancements in science and technology to build breakthrough companies that transform human wellness.
Portfolio business units include: Mikra, a biosciences and consumer wellness company developing and selling innovative products for cellular health; and CannMart, which operates a B2B wholesale distribution business facilitating recreational cannabis sales to Canadian provincial government control boards including for CannMart Labs, a BHO extraction facility producing high margin cannabis 2.0 products. Information on Lifeist and its businesses can be accessed through the links below: Meni Morim CEO Lifeist Wellness Inc.
Ph: 647-362-0390 Email: Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release or has in any way approved or disapproved of the contents of this press release. This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not historical in nature contain forward-looking information.
Forward-looking information can be identified by words or phrases such as “may”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen. The forward-looking information contained herein, including, without limitation, statements related to the anticipated delivery of to customers at the end of the third quarter of this year and expectations relating to Mikra’s future introduction of new products and reaching additional customers in 2024, are made as of the date of this news release and are based on assumptions management believed to be reasonable at the time such statements were made, including without limitation, expectations that the manufacturing of is successfully completed in a timely manner, the effectiveness and benefits of are as anticipated, its expectation that the nutraceutical market will develop as currently anticipated, the nutraceutical market will continue to be a multi-billion dollar high-margin market, the introduction of new products and brands will generate additional revenue, expectations that and other new nutraceutical products to be developed by Mikra will gain market acceptance along with the expansion of the market for nutraceutical products, as well as other considerations that are believed to be appropriate in the circumstances. While we consider these assumptions to be reasonable based on information currently available to management, there is no assurance that such expectations will prove to be correct.
By its nature, forward-looking information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct, and that objectives, strategic goals and priorities will not be achieved. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information in this news release. Such factors include, without limitation: unforeseen delays in the manufacturing and/or sale of , the inability of the Company to develop Mikra’s business as anticipated, unanticipated changes to current regulations that would adversely impact Mikra’s business, unforeseen developments that would delay Mikra’s ability to sell newly developed nutraceutical products, the risk that the expected demand for nutraceutical products in general and those of Mikra in particular does not develop as anticipated and risks relating to the Company’s ability to execute its business strategy and the benefits realizable therefrom.
Additional risk factors can also be found in the Company’s current MD&A filed under the Company’s SEDAR+ profile at www.sedarplus.ca.
Readers are cautioned not to put undue reliance on forward-looking information. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable law. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.
Source: Lifeist Wellness Inc. https://www.ncbi.
nlm.nih.gov/pmc/articles/PMC7601330/ https://www.
mountsinai.org/health-library/supplement/tyrosine https://pubmed.ncbi.
nlm.nih.gov/31413233/.
